IMDX Advances Toward GraftAssure Commercialization with FDA Progress and Early Orders

Event summary

  • IMDX reported Q1 2026 revenues of $32,000, all from laboratory services, with no kitted product revenue yet.
  • The company secured a research-use-only purchase from a European transplant center and anticipates an APAC order soon.
  • IMDX signed its first clinical trial agreement with a top 10 U.S. kidney transplant center for the GALACTIC study.
  • Positive head-to-head data on GraftAssure was presented at EFI2026, with more scheduled for ERA Congress and ATC.
  • IMDX expects FDA marketing authorization for GraftAssureDx later in 2026, with significant U.S. orders anticipated afterward.

The big picture

IMDX is at a pivotal stage in commercializing GraftAssureDx, aiming to disrupt the $2 billion kidney transplant monitoring market with faster, more affordable tests. The company's progress with FDA engagement, early international orders, and positive clinical data positions it to capture a significant share of the decentralized testing market. Success hinges on timely regulatory approvals and rapid adoption by transplant centers.

What we're watching

Regulatory Timing
Whether IMDX can secure FDA marketing authorization by the end of 2026, as anticipated, which is critical for unlocking significant U.S. orders.
Market Adoption
The pace at which transplant centers adopt GraftAssureDx post-FDA approval, particularly given the competitive landscape.
International Expansion
How quickly IMDX can secure and scale orders outside the U.S., particularly in Europe and Asia, following regulatory approvals.

Related topics

Biotechnology